| |
| Frequently Asked Questions |
| |
What is the focus of Carl Zeiss Meditec AG’s business activities?
What are the cornerstones of the Carl Zeiss Meditec strategy?
Which are the main products of Carl Zeiss Meditec AG?
How many people does Carl Zeiss Meditec AG employ? What is the regional presence of Carl Zeiss Meditec AG?
What is the shareholding structure in Carl Zeiss Meditec AG?
What is the shareholding structure of the scattered holdings?
How many Carl Zeiss Meditec shares are outstanding?
At which stock exchanges are Carl Zeiss Meditec shares traded? What are its securities identification numbers?
In which indices are Carl Zeiss Meditec shares represented?
Where can I obtain information on the price movement of Carl Zeiss Meditec shares?
What were the last dividend payments and when were they distributed?
When is the next scheduled AGM?
How and where can a shareholder register for the AGM?
What is the focus of Carl Zeiss Meditec AG's business activities?
Carl Zeiss Meditec AG is one of the world’s leading medical technology companies.
The Company supplies innovative technologies and application-oriented solutions which enable doctors to improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat ophthalmic diseases. In the fields of microsurgery the Company provides innovative visualization solutions. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising future-oriented technologies such as intraoperative radiotherapy.
The Company's around 2,100 employees generated revenues of about EUR 600 million in fiscal year 2007/08 (ended Sept. 30). The headquarters of Carl Zeiss Meditec are located in Jena, Germany. In addition to other subsidiaries in Germany, the Company is represented by over 50 percent of its employees at sites in the USA, Japan, Spain and France.
35 percent of Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and opto-electronic industry. The five independently run business segments of Carl Zeiss AG operate in the future-oriented markets "Medical and Research Solutions", "Industrial Solutions" and "Lifestyle Products". Carl Zeiss AG is headquartered in Oberkochen, Germany. During fiscal year 2007/08 (ended Sept. 30) the company generated revenues of about EUR 2.7 billion. Carl Zeiss has around 13,000 employees in more than 30 countries, including over 8,000 in Germany.
Top
What are the cornerstones of the Carl Zeiss Meditec strategy?
Innovations in all areas of ophthalmology shall continue to be a key driver of the further growth of Carl Zeiss Meditec. Our focus here will be on making time-to-market cycles even shorter in order to further extend our technological leadership in future. We will also continue to improve the effectiveness and efficiency of our global distribution network. The bundling of our sales activities in France is one example of this. This will be supported by an even stronger focus on an all-round customer care concept.
The success story of Carl Zeiss Meditec over the last few years is now to be continued in the second core area of our business activities, neuro/ENT surgery. It is our goal to offer complete solutions for surgical treatments in the future. Our intention is to expand this fi eld, hitherto focused primarily on surgical microscopes and visualisation solutions, to include further related market segments offering interesting growth opportunities. Here we are referring, in particular, to the surgical instruments employed in minimally invasive surgery. A further growth driver in neuro/ENT surgery will be the interlinking of devices and systems to cover the entire treatment chain.
We will continue to exploit external growth opportunities in future wherever logical and possible. The aim of these, on the one hand, is to expand our product and technology base and, on the other hand, to penetrate other addressable market segments to extend our growth into other areas of medical technology.
Top
Which are the main products of Carl Zeiss Meditec AG?
Carl Zeiss Meditec has an extensive and innovative portfolio of products for the diagnosis and treatment of major eye ailments. These include:
- The Cirrus™ HD-OCT is a optical coherence tomography system which provides unique views of retina based on precise segmenting algorithms and high quality 3D images (for example, early diagnosis of glaucoma and retinal disorders)
- The IOLMASTER® for accurate and efficient non-contact measurement of the eye prior to a cataract operation
- The Humphrey® Field Analyzer for static and kinetic measurement of the visual field in support of glaucoma diagnosis
- The new Femtosecondlaser VisuMax® sets standards with precise beam guidance and a balanced relationship of repetition rate and laser pulse energy for accurate and gentle treatment of eye
- VISUCAM™ PRO NM fundus camera for accurate examination of the fundus of the eye without the use of mydriatric pharmaceuticals (for widening the pupils)
- The surgical microscope OPMI Lumera® for ophthalmology with stereo coaxal illumination which enables a successful combination of red reflex and with excellent contrast which is used to illuminate the anterior eye segments from the rear
- AT.Lisa, is the world’s first real multifocal micro-incision (MICS) lens for presbyopia correction with a micro-incision size of up to 1.5 mm.
Top
How many people does Carl Zeiss Meditec AG employ? What is the regional presence of Carl Zeiss Meditec AG?
Carl Zeiss Meditec employs over 2,100 people worldwide. Over 300 of them staff the head office of Carl Zeiss Meditec AG in Jena.
Carl Zeiss Meditec is directly represented in USA, Japan, Germany, Spain and France with its own subsidiaries in these countries. In other countries the company makes use of the powerful and well-focused distribution network of Carl Zeiss AG.
Top
What is the shareholding structure in Carl Zeiss Meditec AG?
65% of the shares are held by Carl Zeiss AG, the remaining 35% are held by freefloat investors.
With the exception of Carl Zeiss AG, no shareholder holds more than 5% of Carl Zeiss Meditec shares.
What is the shareholding structure of the scattered holdings?
About 70% of the scattered holdings are held by institutional investors, the remaining 30% by private investors.
How many Carl Zeiss Meditec shares are outstanding?
Currently 81,309,610 Carl Zeiss Meditec AG shares are outstanding.
At which stock exchanges are Carl Zeiss Meditec shares traded? What are its securities identification numbers?
Carl Zeiss Meditec shares are traded at the Deutsche Börse in Frankfurt (XETRA and on the floor, “Parkett”) as well as at regional stock exchanges in Berlin, Bremen, Düsseldorf, Hamburg, Munich and Stuttgart.
| Stock exchange abbreviation: | AFX |
| ISIN: | DE0005313704 |
| RIC ( Reuters Identification Code): | AFXG.F (floor, "Parkett")
AFXG.DE (XETRA) |
| Bloomberg: | AFX GR |
Top
In which indices are Carl Zeiss Meditec shares represented?
Carl Zeiss Meditec shares are represented in TecDAX, Prime All Share, Technology All Share, International Mid 100, DAXsector All Pharma & Healthcare, DAXsupersector Pharma & Healthcare, HDAX, MIDCAP MKT P-IN and CDAX.
Where can I obtain information on the price movement of Carl Zeiss Meditec shares?
You will find current and historic price information at our Website under "Shares" and those of other providers.
What were the last dividend payments and when were they distributed?
By shareholders' resolution at the Annual General Meeting of
19 May 2009 Carl Zeiss Meditec paid a dividend of € 0.18 for financial year 2007/2008. The payout date was 20 May 2009.
The day on which our shares were traded ex dividend was
20 March 2009.
Top
When is the next scheduled AGM?
The date of the Annual General Meeting 2010 has not yet been fixed.
How and where can a shareholder register for the AGM?
About four weeks prior to the appointed date, shareholders will receive an invitation to the AGM, together with the agenda, through their custodian banks. Shareholders can use the corresponding reply form either to request an admission ticket or to issue a proxy authorisation to the bank. Further formal information can be found in the section “Annual General Meeting” in the current Articles of Association of Carl Zeiss Meditec AG.
In addition, Carl Zeiss Meditec acknowledges the recommendations of the German Corporate Government Codex for the support of shareholders in exercising their right to vote. Accordingly, shareholders may also authorise the company’s proxies to represent them. Further details will be included on the respective invitation to the AGM as soon as it has been issued.
top | |  |